Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,139
  • Shares Outstanding, K 33,380
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,930 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.03

Options Overview Details

View History
  • Implied Volatility 601.90% (+348.78%)
  • Historical Volatility 51.99%
  • IV Percentile 99%
  • IV Rank 70.31%
  • IV High 822.56% on 01/02/26
  • IV Low 79.42% on 05/29/25
  • Expected Move (DTE 9) 1.26 (44.77%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 62
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 2,603
  • Open Int (30-Day) 4,004
  • Expected Range 1.55 to 4.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/26
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.10
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.69 +4.83%
on 02/09/26
3.39 -16.81%
on 01/12/26
-0.56 (-16.57%)
since 01/09/26
3-Month
2.69 +4.83%
on 02/09/26
5.46 -48.32%
on 12/09/25
-1.78 (-38.70%)
since 11/11/25
52-Week
2.33 +20.98%
on 04/08/25
5.46 -48.32%
on 12/09/25
-0.28 (-9.03%)
since 02/11/25

Most Recent Stories

More News
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Multiple patients substantially exceed expected survival at low dose levels; absence of dose- limiting toxicities supports escalation to doses up to 100x higher

ANIX : 2.82 (-5.05%)
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

SAN JOSE, Calif. , Feb. 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.82 (-5.05%)
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine

ANIX : 2.82 (-5.05%)
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

SAN JOSE, Calif. , Dec. 15, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.82 (-5.05%)
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose

ANIX : 2.82 (-5.05%)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

SAN JOSE, Calif. , Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.82 (-5.05%)
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

SAN JOSE, Calif. , Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.82 (-5.05%)
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026

ANIX : 2.82 (-5.05%)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

SAN JOSE, Calif. , Nov. 10, 2025 /PRNewswire/ --  Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.82 (-5.05%)
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial

ANIX : 2.82 (-5.05%)

Business Summary

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

See More

Key Turning Points

3rd Resistance Point 3.31
2nd Resistance Point 3.17
1st Resistance Point 3.07
Last Price 2.82
1st Support Level 2.84
2nd Support Level 2.70
3rd Support Level 2.60

See More

52-Week High 5.46
Fibonacci 61.8% 4.26
Fibonacci 50% 3.89
Fibonacci 38.2% 3.52
Last Price 2.82
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar